Should You Buy Vertex Pharmaceuticals Stock Hand Over Fist Before Jan. 30?
Vertex Pharmaceuticals ( VRTX 3.06%) might be one of those special cases. Should you buy Vertex stock hand over fist before Jan. 30? What's so special about Jan. 30 for Vertex? It's the PDUFA action date set by the U.S. Food and Drug Administration (FDA) for making an approval decision on suzetrigine in treating acute pain.
Wells Fargo & Company Has Lowered Expectations for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price objective cut by Wells Fargo & Company from $555.00 to $460.00 in a report issued on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the pharmaceutical company’s stock.
Therefore, it is wise to be aware of the facts that can impact the stock's prospects. Investors need to pay close attention to Vertex Pharmaceuticals (VRTX) stock based on the movements in the ...
Jefferies analyst Michael Yee has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...
Vertex Pharmaceuticals Inc. closed 18.39% short of its 52-week high of $519.88, which the company reached on November 8th.
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback